ArticleNature2025
RNA neoantigen vaccines prime long-lived CD8
Abstract readClinical Trial, Phase I
In one paragraph
Article in Nature, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 217 papers, 2 of them syntheses that pooled it.
0numbers the graph read from it
0cells of the map it votes in
217citing papers in PubMed, 2 pooled it
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
217 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- Evaluation of translational potential of mRNA vaccine candidate antigens for pancreatic cancer: a systematic review based on clinical evidence and stratified prioritization strategies.Frontiers in immunology · 2026Pooled it
- Mapping the frontiers: a bibliometric perspective on t cell-based immunotherapy in pancreatic cancer since the twenty-first century.Journal of cancer research and clinical oncology · 2025Pooled it
- Pembrolizumab and olaparib in homologous-recombination-deficient metastatic pancreatic cancer: the phase 2 POLAR trial.Nature medicine · 2026Trial
- A Randomized Phase II Study: CRS207/GVAX plus Anti-PD-1 and Anti-CTLA4 Recruits Mesothelin- and mKRAS-Specific T Cells into PDAC.Cancer immunology research · 2026Trial
- Autologous multiantigen-targeted T cell therapy for pancreatic cancer: a phase 1/2 trial.Nature medicine · 2026Trial
- Using a mental model approach to undercut the effects of exposure to mRNA vaccination misconceptions: Two randomized trials.Proceedings of the National Academy of Sciences of the United States of America · 2025Trial
- A bottleneck-first evaluation of antigen delivery platforms for therapeutic cancer vaccines.Materials today. Bio · 2026Review
- Cancer nanomedicine and RNA/Lipid nanoparticle platforms in oncology: developmental evolution, translational barriers, and precision-therapy opportunities.Journal of the Egyptian National Cancer Institute · 2026Review
- Personalized neoantigen-targeting cancer vaccines in ovarian cancer: a phase 1 trial.Nature medicine · 2026Article
- Metal-organic framework nanovaccines for systemic tumour regression.Nature biomedical engineering · 2026Article
- Entering the Age of Specificity in T Cell Immunity.Immunological reviews · 2026Review
- Intratumoral T cell activation kills tumors regardless of T cell specificity.Nature immunology · 2026Article
- Projected lives saved and economic value of mRNA cancer immunotherapies in the United States.Lancet regional health. Americas · 2026Review
- Towards mRNA therapeutics 2.0.Nature reviews. Drug discovery · 2026Review
- Impact of Liver Metastases on Outcomes With Chemotherapy or Immune Checkpoint Inhibitors in Pancreatic Cancer.Immunity, inflammation and disease · 2026Observational
- Recoding by NNature communications · 2026Article
- Immune Checkpoint Inhibitor as a Fifth Component of Lipid Nanoparticles Enables Lymph Node-Targeting and Augments mRNA Vaccine Efficacy.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Article
- Personalized neoantigen mRNA vaccines for pancreatic cancer: the role of lipid nanoparticle delivery systems.Daru : journal of Faculty of Pharmacy, Tehran University of Medical Sciences · 2026Review
- Neoantigen cancer vaccines for gastrointestinal tumors: opportunities and challenges.MedScience · 2026Review
- Predicting Neoantigen Immunogenicity frombioRxiv : the preprint server for biology · 2026Article
157 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
47 authors.
Zachary Sethna *Immuno-Oncology Service, Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Pablo Guasp *Immuno-Oncology Service, Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, NY, USA.ORCID 0000-0002-3655-916X
Charlotte ReicheImmuno-Oncology Service, Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, NY, USA.ORCID 0009-0004-6449-8335
Martina MilighettiImmuno-Oncology Service, Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, NY, USA.ORCID 0000-0003-4170-8796
Nicholas CegliaComputational Oncology Service, Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Erin PattersonThe Olayan Center for Cancer Vaccines, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Jayon LihmThe Olayan Center for Cancer Vaccines, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
George PayneImmuno-Oncology Service, Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Olga LyudovykComputational Oncology Service, Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Luis A RojasImmuno-Oncology Service, Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, NY, USA.ORCID 0000-0001-9218-4086
Nan PangHepatopancreatobiliary Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Akihiro OhmotoImmuno-Oncology Service, Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Masataka AmisakiImmuno-Oncology Service, Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, NY, USA.ORCID 0000-0003-4153-4036
Abderezak ZebboudjImmuno-Oncology Service, Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, NY, USA.ORCID 0000-0002-4708-5211
Zagaa OdgerelImmuno-Oncology Service, Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Emmanuel M BrunoImmuno-Oncology Service, Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, NY, USA.ORCID 0000-0003-2885-1133
Siqi Linsey ZhangImmuno-Oncology Service, Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, NY, USA.ORCID 0009-0001-4436-2746
Charlotte ChengImmuno-Oncology Service, Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Yuval ElhanatiComputational Oncology Service, Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, NY, USA.ORCID 0000-0002-4354-8864
Evelyna DerhovanessianBioNTech, Mainz, Germany.
Luisa ManningBioNTech, Mainz, Germany.
Felicitas MüllerBioNTech, Mainz, Germany.
Ina RheeGenentech, San Francisco, CA, USA.
Mahesh YadavGenentech, San Francisco, CA, USA.
Taha MerghoubMeyer Cancer Center, Weill Cornell Medicine, Weill Cornell Medical College, New York, NY, USA.ORCID 0000-0002-1518-5111
Jedd D WolchokMeyer Cancer Center, Weill Cornell Medicine, Weill Cornell Medical College, New York, NY, USA.
Olca BasturkDepartment of Pathology, Memorial Sloan Kettering Cancer Center, New York, NY, USA.ORCID 0000-0003-2747-1366
Mithat GönenDepartment of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, NY, USA.ORCID 0000-0001-8683-8477
Andrew S EpsteinDepartment of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Parisa MomtazDepartment of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Wungki ParkDepartment of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA.ORCID 0000-0002-8006-3102
Ryan SugarmanDepartment of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Anna M VargheseDepartment of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Elizabeth WonDepartment of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Avni DesaiDepartment of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Alice C WeiHepatopancreatobiliary Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY, USA.ORCID 0000-0002-2505-959X
Michael I D'AngelicaHepatopancreatobiliary Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
T Peter KinghamHepatopancreatobiliary Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Kevin C SoaresHepatopancreatobiliary Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY, USA.ORCID 0000-0002-0406-017X
William R JarnaginHepatopancreatobiliary Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Jeffrey DrebinHepatopancreatobiliary Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Eileen M O'ReillyDepartment of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA.ORCID 0000-0002-8076-9199
Ira MellmanGenentech, San Francisco, CA, USA.ORCID 0000-0002-6132-7299
Ugur SahinBioNTech, Mainz, Germany.ORCID 0000-0003-0363-1564
Özlem TüreciBioNTech, Mainz, Germany.
Benjamin D GreenbaumThe Olayan Center for Cancer Vaccines, Memorial Sloan Kettering Cancer Center, New York, NY, USA.ORCID 0000-0001-6153-8793
Vinod P BalachandranImmuno-Oncology Service, Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, NY, USA. balachav@mskcc.org.ORCID 0000-0002-2956-223X
Funding
X-RAY CRYSTALLOGRAPHYP30CA008748 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI Hongbiao Carl Lekaye · 1985 to 2026
$347.4MDefining neoantigen immunodominance for antigen selection and biomarker discovery in human pancreatic cancer immunotherapyU01CA224175 · NCI · SLOAN-KETTERING INST CAN RESEARCH · PI BALACHANDRAN, VINOD P, LEACH, STEVEN D · 2017 to 2021
$3.1MNCI NIH HHS P30 CA008748NCI NIH HHS U01 CA224175
Abstract
A fundamental challenge for cancer vaccines is to generate long-lived functional T cells that are specific for tumour antigens. Here we find that mRNA-lipoplex vaccines against somatic mutation-derived neoantigens may solve this challenge in pancreatic ductal adenocarcinoma (PDAC), a lethal cancer with few mutations. At an extended 3.2-year median follow-up from a phase 1 trial of surgery, atezolizumab (PD-L1 inhibitory antibody), autogene cevumeran
Indexed as
Antigens, NeoplasmCancer VaccinesCarcinoma, Pancreatic DuctalCD8-Positive T-LymphocytesPancreatic NeoplasmsAgedAntibodies, Monoclonal, HumanizedAntineoplastic Combined Chemotherapy ProtocolsDisease-Free SurvivalFemaleFluorouracilFollow-Up StudiesHumansImmunologic MemoryIrinotecanLeucovorinAntibodies, Monoclonal, HumanizedAntigens, NeoplasmatezolizumabCancer VaccinesFluorouracilfolfirinoxIrinotecanLeucovorinOxaliplatinRNA, Messenger
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.